Form 8-K - Current report:
SEC Accession No. 0001213900-26-048277
Filing Date
2026-04-28
Accepted
2026-04-28 08:03:59
Documents
13
Period of Report
2026-04-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0287908-8k_allarity.htm   iXBRL 8-K 22982
2 PRESS RELEASE, DATED APRIL 27, 2026 ea028790801ex99-1.htm EX-99.1 18287
3 GRAPHIC ea028790801_ex99-1img1.jpg GRAPHIC 2953
  Complete submission text file 0001213900-26-048277.txt   216189

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE allr-20260427.xsd EX-101.SCH 3014
5 XBRL LABEL FILE allr-20260427_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE allr-20260427_pre.xml EX-101.PRE 22358
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0287908-8k_allarity_htm.xml XML 3213
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 26903210
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)